

Layout and/or size adjusted for ease of reading and printing.


PSORCON® E Emollient Ointment
(diflorasone diacetate ointment) 0.05%

Prescribing Information as of December 2001.

Not For Ophthalmic Use

DESCRIPTION

Each gram of **Psorcon E** Emollient Ointment contains 0.5 mg diflorasone diacetate in an ointment base. Chemically, diflorasone diacetate is: 6 α ,9-difluoro - 11 β ,17,21 - trihydroxy - 16 β - methyl-pregna - 1,4 - diene - 3,20 - dione 17,21- diacetate. The structural formula is represented below:



Prescribing Information as of December 2001.

PSORCON^e
Emollient Ointment
diflorasone diacetate
ointment
0.05%

†Aventis



50065610

Psorcon E Emollient Ointment contains diflorasone diacetate in an emollient, occlusive base consisting of polyoxypropylene 15-stearyl ether, stearic acid, lanolin alcohol and white petrolatum.

CLINICAL PHARMACOLOGY

Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.

The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See **DOSAGE AND ADMINISTRATION.**)

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. They are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

INDICATIONS AND USAGE

Topical corticosteroids are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

CONTRAINDICATIONS

Topical steroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

PRECAUTIONS

General: Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity. (See **PRECAUTIONS: Pediatric Use**.)

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.

In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

Information for the Patient: Patients using topical corticosteroids should receive the following information and instructions:

1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
4. Patients should report any signs of local adverse reactions especially under occlusive dressing.
5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on an infant or child being treated in the diaper area, as these garments may constitute occlusive dressings.

Laboratory Tests: The following tests may be helpful in evaluating the HPA axis suppression:

Urinary free cortisol test

ACTH stimulation test

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids.

**PSORCON® E Emollient Ointment
(diflorasone diacetate ointment) 0.05%**

Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

Pregnancy Category C: Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities **not** likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use: Safety and effectiveness of **Psorcon E** (diflorasone diacetate ointment) in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA-axis suppression when they are treated with topical corticosteroids. They are, therefore, also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in pediatric patients.

HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.

ADVERSE REACTIONS

The following local adverse reactions have been reported with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence:

- | | |
|------------------------|---------------------------------|
| 1. Burning | 9. Perioral dermatitis |
| 2. Itching | 10. Allergic contact dermatitis |
| 3. Irritation | 11. Maceration of the skin |
| 4. Dryness | 12. Secondary infection |
| 5. Folliculitis | 13. Skin atrophy |
| 6. Hypertrichosis | 14. Striae |
| 7. Acneiform eruptions | 15. Miliaria |
| 8. Hypopigmentation | |

OVERDOSAGE

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See **PRECAUTIONS**.)

DOSAGE AND ADMINISTRATION

Topical corticosteroids should be applied to the affected area as a thin film from one to four times daily depending on the severity of the condition.

Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions.

If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy initiated.

HOW SUPPLIED

Psorcon E Emollient Ointment is available as follows:

15 gram tube	NDC 0066-0275-17
30 gram tube	NDC 0066-0275-31
60 gram tube	NDC 0066-0275-60

Store at controlled room temperature, 20° to 25° C (68° to 77° F) [see USP].

Prescribing Information as of December 2001.

Rx only

Manufactured for

Dermik Laboratories, Inc.

Berwyn, PA USA 19312

By Pharmacia & Upjohn Company

A subsidiary of Pharmacia Corporation

Kalamazoo, MI, USA 49001

Revised December 2001

50065610

817 503 005

691694

NDA 17-994

(diflorasone diacetate ointment 0.05%)

15 Gram Tube
Code 817 461 000

15 GRAMS
TOPICAL

NDC 0066-0275-17

PSORCON[®]e emollient
(diflorasone diacetate ointment) 0.05%



EMOLLIENT
OINTMENT

Caution: Federal law prohibits dispensing without prescription.

DIRECTIONS AND INDICATIONS: For complete product information, see package insert. For external use only. Not for ophthalmic use. Keep out of the reach of children. Keep tightly closed.


DESCRIPTION: Each gram contains 0.5 mg of diflorasone diacetate in a vehicle consisting of polyoxypropylene 15-stearyl ether, stearic acid, lanolin alcohol and white petrolatum.

Manufactured for
Dermik Laboratories, Inc.
A Rhône-Poulenc Rorer Company
Collegeville, PA, USA 19426
By Pharmacia & Upjohn Company
Kalamazoo, MI, USA 49001

Store at controlled room temperature, 20° to 25° C (68° to 77° F) [see USP].
817 461 000



Exp. date and
Control No. on crimp
TM-7113E



NDA 17-994

(diflorasone diacetate ointment 0.05%)

15 Gram Carton
Code 817 485 000

R-PC



773189

FOR COMPLETE PRODUCT INFORMATION SEE PACKAGE INSERT.

AVERAGE DOSAGE AND INDICATIONS: See package insert.
Literature available to physicians on request. For external use only.
Not for ophthalmic use. Keep out of the reach of children.

817 485 000



NET WT 15 GRAMS TOPICAL NDC 0066-0275-17

PSORCON® emollient ointment
(diflorasone diacetate ointment) 0.05%



Caution: Federal law prohibits dispensing without prescription.

DESCRIPTION: Each gram contains 0.5 mg of diflorasone diacetate in a vehicle consisting of polyoxypropylene 15-stearyl ether, stearic acid, lanolin alcohol and white petrolatum.
Store at controlled room temperature, 20° to 25° C (68° to 77° F) [see USP].

DERMIK LABORATORIES, INC.
Dedicated to Dermatology

Keep tightly closed.

Manufactured for Dermik Laboratories, Inc.
A Rhône-Poulenc Rorer Company, Collegeville, PA, USA 19426
By Pharmacia & Upjohn Company, Kalamazoo, MI, USA 49001

NET WT 15 GRAMS TOPICAL NDC 0066-0275-17

PSORCON® emollient ointment
(diflorasone diacetate ointment) 0.05%



Caution: Federal law prohibits dispensing without prescription.

91

CR-7114D

PSORCON® emollient ointment
(diflorasone diacetate ointment) 0.05%



NDA 17-994

(diflorasone diacetate ointment 0.05%)

**30 Gram Tube
Code 817 462 000**

30 GRAMS
TOPICAL

NDC 0066-0275-31

PSORCON^{®e} emollient
ointment
(diflorasone diacetate ointment) 0.05%



Caution: Federal law prohibits dispensing without prescription.

DIRECTIONS AND INDICATIONS: For complete product information, see package insert.
For external use only. Not for ophthalmic use.
Keep out of the reach of children. Keep tightly closed.

DESCRIPTION: Each gram contains 0.5 mg of diflorasone diacetate in a vehicle consisting of polyoxypropylene 15-stearyl ether, stearic acid, lanolin alcohol and white petrolatum.

Manufactured for

Dermik Laboratories, Inc.
A Rhône-Poulenc Rorer Company
Collegeville, PA, USA 19426
By Pharmacia & Upjohn Company
Kalamazoo, MI, USA 49001

Store at controlled room temperature, 20° to 25° C (68° to 77° F) [see USP].
817 462 000

 **DERMIK LABORATORIES, INC.**
Dedicated to Dermatology™

Exp. date and
Control No. on crimp
TM-7115E

NDA 17-994

(diflorasone diacetate ointment 0.05%)

30 Gram Carton
Code 817 484 000

+

FOR COMPLETE PRODUCT INFORMATION SEE PACKAGE INSERT.
AVERAGE DOSAGE AND INDICATIONS: See package insert. Literature available to physicians on request.
For external use only. Not for ophthalmic use. Keep out of the reach of children.

817 484 000



NET WT 30 GRAMS TOPICAL NDC 0066-0275-31

PSORCON[®] emollient ointment
(diflorasone diacetate ointment) 0.05%
Caution: Federal law prohibits dispensing without prescription.

DESCRIPTION: Each gram contains 0.5 mg of diflorasone diacetate in a vehicle consisting of polyoxypropylene 15-stearyl ether, stearic acid, lanolin alcohol and white petrolatum.

Store at controlled room temperature, 20° to 25° C (68° to 77° F) [see USP].



Manufactured for Dermik Laboratories, Inc.
A Rhône-Poulenc Rorer Company, Collegeville, PA, USA 19426
By Pharmacia & Upjohn Company, Kalamazoo, MI, USA 49001

CH-7116D

Keep lightly closed.

NET WT 30 GRAMS TOPICAL NDC 0066-0275-31

PSORCON[®] emollient ointment
(diflorasone diacetate ointment) 0.05%
Caution: Federal law prohibits dispensing without prescription.

PSORCON[®] emollient ointment
(diflorasone diacetate ointment) 0.05%



8

773384
R-PC

+



NDA 17-994

(diflorasone diacetate ointment 0.05%)

60 Gram Tube
Code 817 463 00060 GRAMS
TOPICAL

NDC 0066-0275-60

PSORCON[®]_e emollient
ointment
(diflorasone diacetate ointment) 0.05%



Caution: Federal law prohibits dispensing without prescription.

DIRECTIONS AND INDICATIONS: For complete product information, see package insert. For external use only. Not for ophthalmic use. Keep out of the reach of children. Keep tightly closed.

DESCRIPTION: Each gram contains 0.5 mg of diflorasone diacetate in a vehicle consisting of polyoxypropylene 15-stearyl ether, stearic acid, lanolin alcohol and white petrolatum.

Manufactured for
Dermik Laboratories, Inc.
A Rhône-Poulenc Rorer Company
Collegeville, PA, USA 19426
By Pharmacia & Upjohn Company
Kalamazoo, MI, USA 49001

Store at controlled room temperature, 20° to 25° C
(68° to 77° F) [see USP].

817 463 000

 **DERMIK LABORATORIES, INC.**
Dedicated to Dermatology[™]

Exp. date and
Control No. on crimp
TM-7117E

NDA 17-994

(diflorasone diacetate ointment 0.05%)

60 Gram Carton
Code 817 483 000


3



773321
R-PC
+

FOR COMPLETE PRODUCT INFORMATION SEE PACKAGE INSERT.

AVERAGE DOSAGE AND INDICATIONS: See package insert. Literature available to physicians on request. For external use only. Not for ophthalmic use. Keep out of the reach of children.



817 483 000

NET WT 60 GRAMS TOPICAL NDC 0066-0275-60



PSORCON[®] emollient ointment
(diflorasone diacetate ointment) 0.05%

Caution: Federal law prohibits dispensing without prescription.

+

DESCRIPTION: Each gram contains 0.5 mg of diflorasone diacetate in a vehicle consisting of polyoxypropylene 15-stearyl ether, stearic acid, lanolin alcohol and white petrolatum.

Store at controlled room temperature, 20° to 25° C (68° to 77° F) [see USP].



CR-7118E

Manufactured for **Dermik Laboratories, Inc.**
A Rhône-Poulenc Rorer Company, Collegeville, PA, USA 19426
By Pharmacia & Upjohn Company, Kalamazoo, MI, USA 49001

Keep tightly closed.



NET WT 60 GRAMS TOPICAL NDC 0066-0275-60



PSORCON[®] emollient ointment
(diflorasone diacetate ointment) 0.05%

Caution: Federal law prohibits dispensing without prescription.

PSORCON[®] emollient ointment
(diflorasone diacetate ointment) 0.05%

NDA 17-994

(diflorasone diacetate ointment 0.05%)

3.5 Gram Tube Code 817 460 000

NET WT NDC 0066-0275-13
3.5 GRAMS

PSORCON emollient ointment
(diflorasone diacetate ointment) 0.05%



Caution: Federal law prohibits dispensing without prescription.

Paraben-Free. Professional Sample.
Not to be sold.

For description, use, and dose—
see package insert.

For external use only. Not for ophthalmic use.

Store at controlled room temperature,
20° to 25° C (68° to 77° F) [see USP].


Manufactured for
Dermik Laboratories, Inc.

A Rhône-Poulenc Rorer Company
Collegeville, PA, USA 19426

By Pharmacia & Upjohn Company
Kalamazoo, MI, USA 49001

817 460 000 Exp. date and
Control No. on crimp
TM-7111D

DERMIK LABORATORIES, INC.
Dedicated to Dermatology™



NDA 17-994

(diflorasone diacetate ointment 0.05%)

3.5 Gram Carton
Code 817 486 000

PSORCON[®] emollient ointment
(diflorasone diacetate ointment) 0.05%



For complete product information see package insert.



DESCRIPTION: Each gram contains 0.5 mg of diflorasone diacetate in a vehicle consisting of polyoxypropylene 15-stearyl ether, stearic acid, lanolin alcohol and white petrolatum.
Store at controlled room temperature, 20° to 25° C (68° to 77° F) [see USP].



Manufactured for Dermik Laboratories, Inc.
A Rhone-Poulenc Rorer Company
Collegeville, PA, USA 19428
By Pharmacia & Upjohn Company
Kalamazoo, MI, USA 49001



PSORCON[®] emollient ointment 0.05%
(diflorasone diacetate ointment)

773445

NDC 0066-0275-13

18 Professional S
NOT FOI

PSORCON[®] emollient ointment
(diflorasone diacetate ointment) 0.05%



NET WT 3.5 grams (each)

Caution: Federal law prohibits dispensing without prescription.

CR-7242A
817 486 000

PSORCON[®] emollient ointment
(diflorasone diacetate ointment) 0.05%



+